Abstract
The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.
Original language | English (US) |
---|---|
Pages (from-to) | 2788-2792 |
Number of pages | 5 |
Journal | Blood |
Volume | 144 |
Issue number | 26 |
DOIs | |
State | Published - Dec 26 2024 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology